Terlipressin 시장 규모 : 유형별, 용도별, 지역별, 범위 및 예측

Terlipressin Market Size And Forecast

Terlipressin Market size was valued at USD 3.9 Billion in 2023 and is projected to reach USD 5.1 Billion by 2030, growing at a CAGR of 6.1% during the forecast period 2024-2030.

The increasing occurrence of liver and kidney decreases with impaired kidney function that is hepatorenal syndrome is stimulating the growth of the Terlipressin Market. The Global Terlipressin Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Terlipressin Market Definition

Terlipressin is used as a vasoactive drug in the management of hypotension, hepatorenal syndrome, and for the treatment of bleeding oesophageal voice. It is similar to vasopressin, is a prohormone of lysine-vasopressin. It is the drug of choice for the treatment of hepatorenal syndrome and is mostly used for the same.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Terlipressin Market Overview

The increasing occurrence of liver and kidney decreases with impaired kidney function that is hepatorenal syndrome is stimulating the growth of the Terlipressin Market. The prevalence of hepatorenal syndrome is unidentified but is predicted to occur in approximately 8-10 percent of individuals. Terlipressin delivers longer biological activity and comparatively lesser side effects than vasopressin and is effective in controlling AVB. It reduces failure to control bleeding and mortality, is the first choice for pharmacological therapy when available. The use of terlipressin as a drug has been proved to be safe, with minimal side effects that usually disappear after dose reduction, and results in an improved outcome in patients with hepatorenal syndrome.

It is approved for use in Europe for patients with hepatorenal syndrome and trials to get it approved in the US are in progress. During findings, it has been found that terlipressin is studied the most for individuals with hepatorenal syndrome and results have shown improved renal function in affected individuals than alternatives. Availability issues are restraining the growth of the Terlipressin Market. At present, terlipressin is not available in the United States and Canada. But is available in New Zealand, Australia, much of Europe, India & UAE, and Pakistan. Easy availability of alternatives such as somatostatin, octreotide, and vapreotide restrains the growth of the market.

Global Terlipressin Market Segmentation Analysis

The Global Terlipressin Market is Segmented on the basis of Type, Application, And Geography.

Terlipressin Market, By Type

• >=98%
• <98%

Based on Type, the market is segmented into >=98% and <98%.

Terlipressin Market, By Application

• Hepatorenal Syndrome (HRS)
• Ascites
• Septic Shock
• Other

Based on Application, the market is segmented into Injection and Other.

Terlipressin Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World
• On the basis of Geography, the Global Terlipressin Market is classified into North America, Europe, Asia Pacific, and the Rest of the world.

Key Players

• The "Global Terlipressin Market" study report will provide a valuable insight with an emphasis on the global market including some of the major players such
• EVER Pharma, Hybio Pharmaceutical, Sun Pharmaceutical Industries Ltd., Shanghai Soho-Yiming Pharmaceuticals, Xi 'an langene biological technology, SGPharma, Maya Biotech, and Hangzhou Huadi Group
• . Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis.

TABLE OF CONTENTS

1. INTRODUCTION OF GLOBAL TERLIPRESSIN MARKET

• 1.1. Overview of the Market
• 1.2. Scope of Report
• 1.3. Assumptions

2. EXECUTIVE SUMMARY

3. RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1. Data Mining
• 3.2. Validation
• 3.3. Primary Interviews
• 3.4. List of Data Sources

4. GLOBAL TERLIPRESSIN MARKET OUTLOOK

• 4.1. Overview
• 4.2. Market Dynamics
  • 4.2.1. Drivers
  • 4.2.2. Restraints
  • 4.2.3. Opportunities
• 4.3. Porters Five Force Model
• 4.4. Value Chain Analysis

5. GLOBAL TERLIPRESSIN MARKET, BY APPLICATION

• 5.1. Overview
• 5.2. Hepatorenal Syndrome (HRS)
• 5.3.Ascites
• 5.4.Septic Shock
• 5.5. Other

6. GLOBAL TERLIPRESSIN MARKET, BY TYPE

• 6.1. Overview
• 6.2. >=98%
• 6.3. <98%

7. GLOBAL TERLIPRESSIN MARKET, BY GEOGRAPHY

• 7.1. Overview
• 7.2. North America
  • 7.2.1. U.S.
  • 7.2.2. Canada
  • 7.2.3. Mexico
• 7.3. Europe
  • 7.3.1. Germany
  • 7.3.2. U.K.
  • 7.3.3. France
  • 7.3.4. Rest of Europe
• 7.4. Asia Pacific
  • 7.4.1. China
  • 7.4.2. Japan
  • 7.4.3. India
  • 7.4.4. Rest of Asia Pacific
• 7.5. Rest of the World
  • 7.5.1. Latin America
  • 7.5.2. Middle East & Africa

8. GLOBAL TERLIPRESSIN MARKET COMPETITIVE LANDSCAPE

• 8.1. Overview
• 8.2. Company Market Ranking
• 8.3. Key Development Strategies

9. COMPANY PROFILES

• 9.1. EVER Pharma
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2. Hybio Pharmaceutical
  • 9.2.1. Overview
  • 9.2.2. Financial Performance
  • 9.2.3. Product Outlook
  • 9.2.4. Key Developments
• 9.3. Sun Pharmaceutical Industries Ltd.
  • 9.3.1. Overview
  • 9.3.2. Financial Performance
  • 9.3.3. Product Outlook
  • 9.3.4. Key Developments
• 9.4. Shanghai Soho-Yiming Pharmaceuticals
  • 9.4.1. Overview
  • 9.4.2. Financial Performance
  • 9.4.3. Product Outlook
  • 9.4.4. Key Developments
• 9.5. Xi 'an langene biological technology
  • 9.5.1. Overview
  • 9.5.2. Financial Performance
  • 9.5.3. Product Outlook
  • 9.5.4. Key Developments
• 9.6. SGPharma
  • 9.6.1. Overview
  • 9.6.2. Financial Performance
  • 9.6.3. Product Outlook
  • 9.6.4. Key Developments
• 9.7. Maya Biotech
  • 9.7.1. Overview
  • 9.7.2. Financial Performance
  • 9.7.3. Product Outlook
  • 9.7.4. Key Developments
• 9.8. Hangzhou Huadi Group
  • 9.8.1. Overview
  • 9.8.2. Financial Performance
  • 9.8.3. Product Outlook
  • 9.8.4. Key Developments

10. Appendix

• 10.1. Related Reports